VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of -$222.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-01.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2019-10-31
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2019-03-31 was -$222.00K.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2018-09-30 was $4.03M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2018-06-30 was $25.89M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 9 month |
|---|---|---|---|
| 2019-03-31 | -$222.00K 10-Q · filed 2019-05-01 | ||
| 2018-09-30 | $4.03M 10-Q · filed 2019-10-31 | $29.92M derived: sum of 2 quarters · filed 2019-10-31 | $29.06M 10-Q · filed 2019-10-31 |
| 2018-06-30 | $25.89M 10-Q · filed 2019-08-01 | $25.03M 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |